OBI Pharma has initiated a Phase 1/2 clinical trial for OBI-902, an antibody-drug conjugate targeting TROP2, an antigen overexpressed in multiple tumor types. The trial aims to verify safety, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors. OBI-902, utilizing the Glycan ADC enabling technology, has shown enhanced stability and antitumor activities in previous studies. The IND for OBI-902 was cleared by the U.S. FDA in April 2025. OBI has licensed the TROP2 targeting antibody from Biosion, Inc. and holds worldwide commercial rights to OBI-902. OBI’s GlycOBI® ADC technology has shown improved stability and antitumor activity in animal studies, providing advantages in manufacturing ADC products.

OBI Pharma, a global oncology company, is focusing on developing novel therapeutic agents for patients with high unmet medical needs. OBI’s pipeline includes TROP2 ADCs, such as OBI-902, Nectin-4, HER2 x TROP2, and cMET x HER3 ADCs. The company’s proprietary ADC enabling technology, GlycOBI®, has enabled the creation of next-generation ADCs with improved therapeutic index. OBI also has a small-molecule prodrug, OBI-3424, targeting the AKR1C3 enzyme highly expressed in tumors. OBI’s technology includes GlycOBI®, EndoSymeOBI®, ThiOBI®, and HYPrOBI®. The company has developed a unique ADC technology that enhances antitumor activity and stability in various in vivo studies.

Read more at GlobeNewswire: OBI Pharma Announces Phase 1/2 Study Initiation for